Estudios citogenéticos y moleculares en leucemia mieloide crónica

Giere, Isabel Amanda; Larripa, Irene Beatríz.
Bol. Acad. Nac. Med. B.Aires ; 71(1): 101-8, jun. 1993. tab, ilus
Artículo en Español | BINACIS | ID: bin-24648

Documentos relacionados

  1. Clinical applications of abnormal DNA methylation in chronic myeloid leukemia.
  2. Single amino acid-based PROTACs trigger degradation of the oncogenic kinase BCR-ABL in chronic myeloid leukemia (CML).
  3. Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group.
  4. Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy.
  5. Chronic Myeloid Leukemia During Pregnancy with Placental Involvement: Case Report and Literature Review.
  6. Análisis de la presencia de trisomía 8 en las diferentes fases de leucemia mieloide crónica.
  7. Measurable residual disease in chronic myeloid leukemia.
  8. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
  9. Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with CML.
  10. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study.